Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Thomas, Kyla H ^a,c   Martin, Richard M ^a   Potokar, John ^a   Pirmohamed, Munir ^b   Gunnell, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c South Gloucestershire Council   (United Kingdom)

Author keywords

Adverse drug reaction; Adverse effects; Depression; Non fatal suicidal behaviour; Self injury; Suicide; Yellow card

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DIAZEPAM; DULOXETINE; EFAVIRENZ; ESCITALOPRAM; FLUOXETINE; FLUPENTIXOL; INFLIXIMAB; ISOTRETINOIN; MEFLOQUINE; MIRTAZAPINE; OLANZAPINE; PARACETAMOL; PAROXETINE; QUETIAPINE; RIMONABANT; RISPERIDONE; SERTRALINE; TEMAZEPAM; TRAMADOL; UNINDEXED DRUG; VARENICLINE; VENLAFAXINE; ZOPICLONE; ANTIDEPRESSANT AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; DEPRESSION; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; SMOKING CESSATION; SUICIDAL BEHAVIOR; UNITED KINGDOM; NATIONAL HEALTH SERVICE; SUICIDE;

ANTIDEPRESSIVE AGENTS; DEPRESSION; GREAT BRITAIN; HUMANS; STATE MEDICINE; SUICIDE;

EID: 84964313467     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-54     Document Type: Article

References (40)

1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004, 329:15-19.
2. European Medicines Agency: The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. London, UK: European Medicines Agency; 2008.
3. Kuehn BM: Studies linking smoking-cessation drug with suicide risk spark concerns. JAMA 2009, 301:1007-1008.
4. BBC Panorama: The Secrets of Seroxat. 2002. http://news.bbc.co.uk/panorama/hi/front_page/newsid_8425000/8425414.stm.
5. BBC Three: Dying for clear skin. 2012. http://www.bbc.co.uk/programmes/p00xxy87.
6. Waller PC, Wood SM, Langman MJS, Breckenridge AM, Rawlins MD: Review Of Company Postmarketing Surveillance Studies. BMJ 1992, 304:1470-1472.
7. Bygdell M, Brunlöf G, Wallerstedt SM, Kindblom JM: Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmacoepidemiol Drug Saf 2012, 21:79-86.
8. Patten SB, Love EJ: Neuropsychiatric adverse drug reactions: passive reports to Health and Welfare Canada's Adverse Drug Reaction Database (1965-present). Int J Psychiatry Med 1994, 24:45-62.
9. Vilhelmsson A, Svensson T, Meeuwisse A, Carlsten A: What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association. BMC Clin Pharmacol 2011, 11:16.
10. Robertson HT, Allison DB: Drugs Associated with More Suicidal Ideations Are also Associated with More Suicide Attempts. Plos One 2009, 4:e7312.
11. Hawton K, van Heeringen K: Suicide. The Lancet 2009, 373:1372-1381.
12. European Parliament, Council of the European Union: Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official J Eur Union 2010, L348:74-79.
13. ATC/DDD Index 2014. http://www.whocc.no/atc_ddd_index/.
14. Speirs CJ: Prescription related adverse reaction profiles and their use in risk-benefit analysis. In Iatrogenic diseases. 3rd edition. Edited by D'Arcy PF, Griffin JP. Oxford: Oxford university press; 1986:93-101.
15. Bradford H: The environment and disease: association or causation? ProcRSocMed 1965, 58:295-300.
16. Pariente A, Daveluy A, Laribiere-Benard A, Miremont-Salame G, Begaud B, Moore N: Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA. Drug Saf 2009, 32:441-447.
17. Gunnell D, Irvine D, Wise L, Davies C, Martin RM: Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009, 339:b3805.
18. Davis S, King B, Raine JM: Spontaneous reporting-UK. In Pharmacovigilance. 2nd edition. Edited by Mann RD, Andrews EB. Chichester, West Sussex: John Wiley & Sons; 2007:199-215.
19. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D: Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005, 330:389-393.
20. Hazell L, Shakir SAW: Under-Reporting of Adverse Drug Reactions: A Systematic Review. Drug Safety 2006, 29:385-396.
21. Martin RM, Kapoor KV, Wilton LV, Mann RD: Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998, 317:119-120.
22. Hawton K, Bergen H, Casey D, Simkin S, Palmer B, Cooper J, Kapur N, Horrocks J, House A, Lilley R, Noble R, Owens D: Self-harm in England: a tale of three cities-Multicentre study of self-harm. Soc Psychiatr Psychiatr Epidemiol 2007, 42:513-521.
23. Dal Pan GJ, Lindquist M, Gelperin K: Postmarketing Spontaneous Pharmacovigilance Reporting Systems. In Textbook of Pharmacoepidemiology. Chichester, UK: John Wiley & Sons Ltd; 2013:99-117.
24. Evans SJ, Waller PC, Davis S: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001, 10:483-486.
25. Aagaard L, Hansen EH: Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011. BMC Pharmacol Toxicol 2013, 14:1-9.
26. Martin RM, May M, Gunnell D: Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001-2004. Br J Clin Pharmacol 2006, 61:224-228.
27. Stobaugh DJ, Deepak P, Ehrenpreis ED: Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. J Am Acad Dermatol 2013, 69:393-398.
28. Kim CJ, Berlin JA: The Use of Meta-analysis in Pharmacoepidemiology. In Textbook of Pharmacoepidemiology. Edited by Strom BL, Kimmel SE. West Sussex, England: John Wiley & Sons, Ltd; 2006:353-365.
29. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. The Lancet 2004, 363:1341-1345.
30. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. The Lancet 2007, 370:1706-1713.
31. Medicines and Healthcare products Regulatory Agency: Varenicline:adverse psychiatric reactions, including depression. Drug Safety Update 2008, 2:2-3.
32. Buggy Y, Cornelius V, Fogg C, Kasliwal R, Layton D, Shakir SA: Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England. Drug Saf 2013, 36:521-531.
33. Harrison-Woolrych M, Ashton J: Psychiatric Adverse Events Associated with Varenicline: An Intensive Postmarketing Prospective Cohort Study in New Zealand. Drug Saf 2011, 34:763-772.
34. Thomas KH, Martin RM, Davies N, Metcalfe C, Windmeijer F, Gunnell D: Smoking cessation treatment and the risk of depression, suicide and self-harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ 2013, 347:f5704.
35. US Food and Drug Administration: Updated information on Leukotriene Inhibitors: Montelukas t (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR). In Book Updated information on Leukotriene Inhibitors: Montelukas t (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR); 2009.
36. Philip G, Hustad C, Noonan G, Malice M-P, Ezekowitz A, Reiss TF, Knorr B: Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009, 124:691-696. e696.
37. Jick H, Hagberg KW, Egger P: Rate of Suicide in Patients Taking Montelukast. Pharmacotherapy 2009, 29:165-166.
38. Hennen J, Baldessarini RJ: Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 2005, 73:139-145.
39. Kenedi C, Goforth H: A Systematic Review of the Psychiatric Side-Effects of Efavirenz. AIDS Behav 2011, 15:1803-1818.
40. Gibbons RD, Mann JJ: Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned? Drug Saf 2011, 34:375-395.